What were the main drivers of IDEXX's revenue growth in 2005?

The primary drivers of IDEXX's revenue growth in 2005 were its Companion Animal Group (CAG), which saw a significant increase due to strong performance in instruments, consumables, rapid assays, and especially its reference laboratory and consulting services. Acquisitions in the veterinary reference laboratory space also contributed substantially to CAG's growth. The Food Diagnostics Group also showed robust growth, primarily from production animal products.

How did the company manage its profitability in 2005 amidst growth and acquisitions?

IDEXX maintained a relatively stable gross profit margin of approximately 50.6% in 2005. While operating expenses increased due to factors like acquisition integration costs, expansion of sales and marketing efforts, and R&D investments, the company's overall operating income still grew by 6.8%. The slight decrease in operating margin was attributed to these increased expenses and the impact of acquisitions.

What is IDEXX's strategy for its key business segments, particularly Companion Animal Group (CAG)?

In the CAG segment, IDEXX focuses on providing integrated disease-management solutions by leveraging a broad range of products and services, including point-of-care diagnostics, laboratory testing, and practice information management systems. The company aims to enhance connectivity between these offerings to provide superior diagnostic information and streamline veterinary practice operations. Strategic acquisitions of reference laboratories and digital radiography businesses were key to this strategy in 2005.

What are the key risks and uncertainties highlighted by IDEXX in its 2005 10-K?

IDEXX highlighted several key risks, including dependence on developing and marketing new products, the ability to integrate acquisitions, competition, reliance on a limited number of suppliers for critical components, and the impact of government regulations across its various product lines. International revenue, comprising 34% of total revenue, also introduced currency exchange rate risks and other geopolitical uncertainties.

IDXX 10-K FY2005 Annual Report — Revenue, Net Income, EPS

Summary

IDEXX Laboratories, Inc. (IDXX) presented its fiscal year 2005 performance in this 10-K filing. The company demonstrated robust revenue growth, increasing by 16% to $638.1 million, driven primarily by its Companion Animal Group (CAG). This segment saw a significant 16.1% revenue increase, fueled by strong performance in instruments and consumables, rapid assays, and a substantial 31.9% surge in reference laboratory and consulting services, bolstered by strategic acquisitions. The company also reported positive growth in its Water and Food Diagnostics Groups (FDG), with FDG showing a notable 27.7% revenue increase. IDEXX maintained a stable gross profit margin of approximately 50.8% in 2005, reflecting its ability to manage costs effectively amidst growth and integration activities. Despite an increase in operating expenses, partly due to acquisition integration and expanded sales efforts, the company achieved a solid operating income, though the operating income margin slightly decreased. IDEXX continues to invest in research and development, signaling a commitment to future innovation and market leadership in the animal health and diagnostics sectors.

Key Highlights

1IDEXX reported a 16% year-over-year revenue increase, reaching $638.1 million in 2005.
2The Companion Animal Group (CAG) was the primary growth driver, with revenue up 16.1% to $520.8 million, significantly boosted by veterinary reference laboratory and consulting services.
3The Food Diagnostics Group (FDG) experienced strong growth of 27.7%, reaching $60.5 million, largely driven by production animal products.
4Gross profit margin remained stable at approximately 50.6% for the total company in 2005.
5Operating income increased by 6.8% to $115.3 million, although the operating margin slightly decreased to 18.1% from 19.7% in the prior year.
6The company continued to invest in its future, with Research and Development expenses increasing by 15.6% to $40.9 million.
7IDEXX actively repurchased shares, buying back approximately 1.99 million shares for $123.8 million during 2005, indicating a commitment to returning value to shareholders.

IDEXX LABORATORIES INC /DE Annual Report, Year Ended Dec 31, 2005

Summary

Key Highlights

Frequently Asked Questions